“Gut Microbiota Metabolites As A New Therapeutic Target In Patients With Coronary Artery Disease And Atrial Fibrillation”, Journal of Pharmaceutical Negative Results, pp. 1221–1227, Jan. 2023, doi: 10.47750/pnr.2023.14.02.157.